The latest FDA Black Box Warning about hepatitis C treatments demonstrates why it's imperative that your Plan implement methods for protecting your beneficiaries against the dangers of new drugs. After all,
HR Execs: Do you think your PBM's shake-down of hepatitis C manufacturers really decreased your health plan's costs? If so, you should follow Ronald Reagan’s approach with the Russians: "Doveryai no
